We are live on ! Find out more
PEAR

Pear Therapeutics, Inc. Class A Common Stock
PEAR

Delisted

PEAR was delisted on the 18th of April, 2023.

Back to rankings

85 hedge funds and large institutions have $257M invested in Pear Therapeutics, Inc. Class A Common Stock in 2021 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 13 increasing their positions, 9 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

163% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 8

44% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 9

27% more capital invested

Capital invested by funds: $203M → $257M (+$54.6M)

18% more funds holding

Funds holding: 72 → 85 (+13)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
85
Holders Change
+13
Holders Change %
+18.06%
% of All Funds
1.49%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
21
Increased
13
Reduced
9
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BCM
BlueCrest Capital Management
Jersey
+$9.89M
2
MF
Magnetar Financial
Illinois
+$8.58M
3
WAM
Weiss Asset Management
Massachusetts
+$7.47M
4
OPU
Omni Partners US
California
+$6.57M
5
SRF
Silver Rock Financial
California
+$6.27M

Top Sellers

Rank Fund Capital Flow
1
KCM
Kingstown Capital Management
New York
-$2.96M
2
MP
Mangrove Partners
Connecticut
-$2.96M
3
PI
PEAK6 Investments
Illinois
-$1.98M
4
CL
CSS LLC
Illinois
-$1.56M
5
PAMP
Polar Asset Management Partners
Ontario, Canada
-$1.48M
Name Holding Trade Value Shares
Change 		Change in
Stake
GCM
26
Ghisallo Capital Management
Massachusetts
$3.43M – – –
Hudson Bay Capital Management
27
Hudson Bay Capital Management
Connecticut
$3.41M – – –
TCA
28
Taconic Capital Advisors
New York
$3.09M – – –
PSAMP
29
P. Schoenfeld Asset Management (PSAM)
New York
$2.98M – – –
D.E. Shaw & Co
30
D.E. Shaw & Co
New York
$2.76M – – –
UOC
31
UBS O'Connor
Illinois
$2.48M – – –
AWG
32
Alpha Wave Global
New York
$2.29M +$1.01M +102,288 +80%
Verition Fund Management
33
Verition Fund Management
Connecticut
$2.15M -$1.31M -132,538 -38%
OCM
34
Oribel Capital Management
New York
$2.1M – – –
BI
35
Bulldog Investors
New Jersey
$2.05M -$4.24K -429 -0.2%
RCM
36
Ratan Capital Management
Florida
$1.99M +$1.98M +200,000 New
WCMNY
37
Westchester Capital Management (New York)
New York
$1.97M +$1.96M +197,927 New
AA
38
AQR Arbitrage
Connecticut
$1.83M -$49.4K -5,000 -3%
WP
39
Woodline Partners
California
$1.49M – – –
LP
40
LMR Partners
United Kingdom
$1.49M – – –
PMAM
41
Picton Mahoney Asset Management
Ontario, Canada
$1.49M – – –
AGM
42
Alpine Global Management
New York
$1.49M +$1.48M +150,000 New
State of Wisconsin Investment Board
43
State of Wisconsin Investment Board
Wisconsin
$1.49M +$1.48M +150,000 New
HI
44
HBK Investments
Texas
$1.39M – – –
RCM
45
Rivernorth Capital Management
Florida
$1.25M +$1.25M +126,267 New
Blackstone Inc
46
Blackstone Inc
New York
$1.24M – – –
SSA
47
Schonfeld Strategic Advisors
New York
$1.06M +$193K +19,533 +22%
AGC
48
Angelo Gordon & Co
New York
$994K – – –
FTCM
49
Fir Tree Capital Management
New York
$994K – – –
SCC
50
Spring Creek Capital
Kansas
$994K – – –
1
2
3 4

PEAR Hedge Fund Activity: Q3 2021 in Review

85 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Pear Therapeutics, Inc. Class A Common Stock (PEAR) for Q3 2021, worth a combined $257M — up 27% from $203M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new PEAR positions and 8 closed out — a net gain of 13 holders — while 13 added to existing stakes and 9 trimmed.

The largest buyer was BlueCrest Capital Management, opening a new position worth an estimated $9.89M. The largest seller was Kingstown Capital Management, exiting entirely with an estimated $2.96M sold.

  • 85 institutional investors held Pear Therapeutics, Inc. Class A Common Stock (PEAR) as of Q3 2021, up from 72 in Q2 2021.
  • Funds reported $257M of Pear Therapeutics, Inc. Class A Common Stock stock for Q3 2021, up 27% quarter-over-quarter.
  • 21 funds opened new Pear Therapeutics, Inc. Class A Common Stock positions in Q3 2021 and 8 closed out, a net change of +13 holders.
  • The largest Pear Therapeutics, Inc. Class A Common Stock buyer in Q3 2021 was BlueCrest Capital Management, an estimated $9.89M added.
  • The largest Pear Therapeutics, Inc. Class A Common Stock seller in Q3 2021 was Kingstown Capital Management, an estimated $2.96M sold.

Based on aggregated 13F filings for Q3 2021.